FOR USE ANYTIME

CONTACT: Susan Benton Russell
Phone: 310.697.3488
susan@bentoncommunications.com

Thoratec Corporate Fact Sheet

Established: Thoratec® Corporation was incorporated in March of 1976 and began publicly selling shares of its stock in the spring of 1981 (NASDAQ:THOR). In February 2001, Thoratec completed a merger with Thermo Cardiosystems Inc. (AMEX: TCA). Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for advanced heart failure patients.

Mission: Thoratec innovates and delivers technologies that enable a full range of therapies to save, support and restore failing hearts, allowing patients to reclaim their lives.

Overview: Thoratec develops, manufactures and markets proprietary medical devices used for circulatory support, vascular graft applications, point-of-care diagnostic test systems and skin incision products. A world leader in products to treat cardiovascular disease, Thoratec offers the broadest range of mechanical circulatory support devices available. With its strong commitment to clinical affairs and research, Thoratec Corporation is also a frontrunner in a wide range of emerging markets driven by the development of advanced technology and the approval of new therapy and product indications.

Thoratec Product Portfolio

Thoratec® PVAD™ (Paracorporeal Ventricular Assist Device): The Thoratec PVAD provides maximum versatility for physicians in meeting the left, right or bi-ventricular support needs of advanced heart failure patients requiring acute (weeks) or intermediate (months) support with the opportunity for home discharge. With more than 25 years of clinical use, the PVAD can support a wide range of patients with advanced heart failure. Today, more than 4,300 PVADs have been used in more than 240 heart centers worldwide. The device is FDA approved for Bridge-to-Transplantation (BTT) and Post-Cardiotomy Recovery from open-heart surgery.

Thoratec® IVAD™ (Implantable Ventricular Assist Device): The Thoratec IVAD is based on the reliable and clinically established Thoratec PVAD. The result is an implantable VAD with proven technology that can support an extensive array of patients. The IVAD - more -
Device): is the only implantable biventricular support option for advanced heart failure patients requiring intermediate (months) or chronic (years) biventricular support. The IVAD received European Union CE Mark authorization in 2003 and FDA approval in the U.S. in 2004. The IVAD has been implanted in more than 560 patients worldwide who require intermediate-to-chronic circulatory support.

HeartMate® I (XVE) LVAS (Left Ventricular Assist System): With more than 5,500 implants in 36 countries for BTT or to provide a life-saving alternative for advanced heart failure patients ineligible for cardiac transplantation, known as Destination Therapy (DT), the HeartMate I is recognized as the worldwide LVAD market leader. The first iteration of HeartMate I was a pneumatic powered LVAD, and was approved in 1994 by the FDA. Today, the HeartMate XVE LVAS, approved in 2001, is the only mid-to-long-term device that does not require systemic anticoagulation.

HeartMate II® LVAS (Left Ventricular Assist System): FDA-approved for BTT in April 2008 and DT in January 2010, the HeartMate II LVAS is a miniaturized mechanical circulatory support device designed to restore hemodynamic function by pumping oxygenated blood throughout the body. The HeartMate II is designed to provide long-term cardiac support for patients who have advanced-stage heart failure. In total, more than 5,000 patients have been implanted with HeartMate II through trial enrollment and commercial use worldwide.¹ There are more than 200 medical centers worldwide that are implanting HeartMate II. For a list of centers visit: http://www.thoratec.com/patients-caregivers/about-heartmateII.aspx

Thoratec® CentriMag® Blood Pump: The Thoratec CentriMag Blood Pump is an external device for short-term circulatory support consisting of a single-use blood pump, a motor and a device console. As the first and only magnetically levitated blood pump cleared by the FDA, the CentriMag is a technologically advanced acute circulatory support device that provides rapid hemodynamic stabilization.

Executive Officers: Gary F. Burbach – President and Chief Executive Officer
David V. Smith - Executive Vice President and Chief Financial Officer
David A. Lehman - Senior Vice President and General Counsel

Employees: More than 600 worldwide

World Headquarters: Thoratec Corporation
6035 Stoneridge Drive
Pleasanton, CA 94588
Phone: 1 (800) 528-2577
Fax: (925) 847-8574

¹ Thoratec date on file
The company also has facilities in Burlington, Massachusetts; Rancho Cordova, Calif.; Roseville, Minnesota and Huntingdon, Cambridgeshire, UK.

Internet: www.thoratec.com

+ CentriMag is a registered trademark of and is manufactured by Levitronix, LLC.

# # #

B100-1110